Neurology® Neuroimmunology and Neuroinflammation (“N2”) debuted in 2014, becoming a journal devoted to neurologists, translational scientists, and trainees engaged in clinical and translational neuroimmunology research, patient care, and education of neuroinflammatory disorders. Its mission has been to publish original research and in-depth reviews on topics of neuroimmunology affecting diverse neurologic diseases, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), paraneoplastic diseases, neuromuscular disorders, neuroinfectious diseases, neurodegenerative diseases (e.g., Alzheimer disease and Parkinson disease), and animal models of these diseases.1 After its launch, which was led by Dr. Richard Ransohoff, the first editor-in-chief, Dr. Josep Dalmau accepted the helm as editor-in-chief and guided N2 to prominence among the top tier of neurology and immunology journals. This achievement was celebrated in a recent issue by the publication of a series of reviews that highlighted many of the most cited publications.2-6 The success of N2 was made possible by the many authors, reviewers, editors, the Neurology® journals staff, and the N2 readers, representing the neuroimmunology community.
Now, N2 enters its second decade. The breadth of topics in neuroimmunology and neuroinflammation covered by the journal has been a strength, and our goal is to continue to publish high-quality original research and reviews. We have seen an expansion in the number of neurologic disorders with an autoimmune origin and infectious diseases with neurologic consequences.2-4,6,7 In years past, neuroimmunology was dominated by investigations focused on T and B lymphocytes, the cells within the adaptive immune system, the identification of their target antigens, and how those lymphocytes initiate inflammation. Recently, the field of neuroimmunology has seen a rapid growth in publications focused on innate immune cells (e.g., microglia, macrophages, and astrocytes) and how, independent of lymphocytes, those cells may contribute to the progressive phase of MS, primary neurodegenerative diseases, and other neuroinflammatory conditions. As N2 moves forward, we wish to encourage more reports as those topics advance.
We are excited to introduce new members of the N2 editorial team:
Dr. Romana Höftberger, Medical University of Vienna, is a renowned neuropathologist who specializes in the neuropathologic features of antibody-mediated autoimmune diseases. Dr. Höftberger served as a member of the N2 editorial board and now joins us as an associate editor.
Dr. Anne-Katrin Pröbstel, University of Bonn, is a clinician-scientist and leading neuroimmunologist accomplished in elucidating the roles of B cells and antibodies and their crosstalk with gut microbiota in MS, MOGAD, NMOSD, and autoimmune encephalitis. Dr. Pröbstel began as a section editor in mid-2024 and now will serve as our deputy editor.
We are exceptionally pleased that Drs. Josep Dalmau (paraneoplastic syndromes and noninfectious encephalitides), Dennis Kolson (neuroinfectious diseases), and Marinos Dalakas (neuromuscular and peripheral diseases) will continue to serve as associate editors. We are fortunate to have a large editorial board representing a broad spectrum of expertise.
We continue to encourage your comments, editorials, help with reviewing, and most of all, submissions: clinical, animal, and bench research; clinical trials; reviews; case reports; and case series. The field of neuroimmunology is advancing nearly at Mach speed. N2 has benefited from your enthusiasm. We look forward to your continued support with contributions in the coming years.
Study Funding
The author reports no targeted funding.
Disclosure
S.S. Zamvil is supported by NIH grants 1 R01 AI131624-01A1 and 1 R01 AI170863-01A1, the Sumaira Foundation, and the Weill Institute for Neurosciences and receives a stipend as editor of Neurology® Neuroimmunology & Neuroinflammation. Go to Neurology.org/NN for full disclosures.
References
- 1.Ransohoff RM. Call for papers: Neurology: Neuroimmunology & Neuroinflammation, a new neurology journal. Neurology. 2014;82(8):648-649. doi: 10.1212/wnl.0000000000000159 [DOI] [Google Scholar]
- 2.Dalmau J, Dalakas MC, Kolson DL, Probstel AK, Paul F, Zamvil SS. Ten years of Neurology® Neuroimmunology & Neuroinflammation: decade in review. Neurol Neuroimmunol Neuroinflamm. 2025;12(1):e200363. doi: 10.1212/NXI.0000000000200363 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Querol L, Dalakas MC. The discovery of autoimmune nodopathies and the impact of IgG4 antibodies in autoimmune neurology. Neurol Neuroimmunol Neuroinflamm. 2025;12(1):e200365. doi: 10.1212/NXI.0000000000200365 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Nath A, Kolson DL. Reemerging infectious diseases and neuroimmunologic complications. Neurol Neuroimmunol Neuroinflamm. 2025;12(1):e200356. doi: 10.1212/NXI.0000000000200356 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ransohoff RM. Selected aspects of the neuroimmunology of cell therapies for neurologic disease: perspective. Neurol Neuroimmunol Neuroinflamm. 2025;12(1):e200352. doi: 10.1212/NXI.0000000000200352 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Graus F, Sabater L, Gaig C, et al. Anti-IgLON5 disease 10 years later: what we know and what we do not know. Neurol Neuroimmunol Neuroinflamm. 2025;12(1):e200353. doi: 10.1212/NXI.0000000000200353 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Moseley CE, Virupakshaiah A, Forsthuber TG, Steinman L, Waubant E, Zamvil SS. MOG CNS autoimmunity and MOGAD. Neurol Neuroimmunol Neuroinflamm. 2024;11(5):e200275. doi: 10.1212/NXI.0000000000200275 [DOI] [PMC free article] [PubMed] [Google Scholar]